March 19, 2018 07:55 AM EDT
R&D

With No­var­tis and Roche gun­ning to carve up Eylea fran­chise, Re­gen­eron has an­oth­er PhI­II suc­cess sto­ry to tell

John Carroll

Editor & Founder

Work­ing fu­ri­ous­ly to stay ahead of two pow­er­house ri­vals in No­var­tis and Roche, Re­gen­eron to­day is run­ning out a promis­ing set of fresh top-line da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times